In Brief: Perkin-Elmer/PerSeptive Biosystems
This article was originally published in The Gray Sheet
Executive SummaryPerkin-Elmer/PerSeptive Biosystems: Hart-Scott-Rodino antitrust review of Perkin-Elmer's proposed $360 mil. acquisition of PerSeptive is extended as a result of a Department of Justice request for additional information related to the transaction. A definitive agreement for the deal was announced Aug. 25 ("The Gray Sheet" Sept. 1, p. 6). Both firms offer mass spectrometry products that enable lab technicians to analyze and sequence peptide and protein biomolecules; the firms maintain that their respective technologies are used in different phases of the drug discovery process. In addition to regulatory approval, the deal is contingent on a vote by PerSeptive shareholders, a meeting of which is slated for Dec. 4...
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.